BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld
BioWorld
June 4, 2008
View Archived Issues
Vertex Sells Royalty Rights to HIV Inhibitors for $160 Million
Vertex Pharmaceuticals Inc. is unloading two HIV protease inhibitors it helped develop in a $160 million deal with GlaxoSmithKline plc in which it agreed to sell rights to future royalties for Lexiva and Agenerase. (BioWorld Today)
Read More
New Data Show Avant's Vaccine Doubles Survival in Brain Cancer
Read More
IRX Brings in $25M to Advance Lead Cancer Compound, IRX-2
Read More
NewCo News: NexBio Cuts Off Influenza Virus from its Entry Route
Read More
Gen-Probe Makes Counterbid for Diagnostics Firm Innogenetics
Read More
Other News To Note
Read More
ASCO Roundup: Incyte Slips on Myelofibrosis Data; ImmunoGen Falls, Too
Read More
Clinic Roundup
Read More